Andarix Pharmaceuticals is a pioneer in the field of targeted therapies for personalized medicine. With a commitment to improving patient outcomes, the company is developing and commercializing novel cancer therapies that specifically target the patients most likely to respond. Their lead product, Tozaride®, is currently in Phase 2 clinical trials and demonstrates the power of molecular targeting at the molecular level.

Tozaride® is designed to treat specific cancers with precision, ensuring that the right patients receive the right therapy. What sets Andarix apart is their companion diagnostic, which identifies patients with the corresponding molecular signature that makes them ideal candidates for therapy. This innovative approach maximizes treatment efficacy and minimizes potential side effects.

Andarix focuses on peptide targeted radiotherapy, a groundbreaking technique validated in clinical studies and routine use in Europe. By leveraging the specific attributes of radiotherapy, cancer cells are unable to escape the lethal damage caused by targeted radiation. To stay on top of the latest advancements and breakthroughs, Andarix regularly provides news and events related to their products.

They are actively involved in conferences and presentations, showcasing their technology and sharing their clinical strategies and results. With a focus on personalized and targeted medicine, Andarix is at the forefront of revolutionizing cancer treatment